BRIEF: 111 Inc.’s revenue drops in second quarter

YI.US

Drug seller 111 Inc. (YI.US) said on Wednesday its revenue fell 6.4% year-on-year to 3.2 billion yuan ($450 million) in the second quarter, as revenue for its core business of selling drugs to pharmacies and medical institutions fell by 6.2%. Its much smaller business of selling drugs directly to consumers also fell 9.6% for the quarter year-on-year.

The company’s operating costs and expenses fell by a similar 6.3% to 3.2 billion yuan from 3.4 billion yuan in the year-ago period. As a result, 111 Inc. reported positive income from operations of $100,000 for the quarter. But its net loss widened to 19.5 million yuan from 14 million yuan a year earlier.

The company’s shares fell 6.2% on Wednesday after the report’s publication. The stock is down 40% over the last six months.

By Doug Young

To subscribe to Bamboo Works free weekly newsletter, click here

,
,

Related Articles

RELATED ARTICLES

  1. Kelun-Biotech reported rising sales of its signature cancer drug
    Precision cancer drugs show promise for Kelun-Biotech
    6990.HK
  2. BRIEF: Sands China second-quarter profit drops 13%
    1928.HK
  3. Second-quarter box office blues dampen diversifying Maoyan
    1896.HK
  4. BRIEF: Legend Biotech’s revenue rises 36% in second quarter
    LEGN.US
  5. BRIEF: NetEase revenue, profit rise in second quarter
    9999.HK
    NTES.US
Discover hidden China stock gems in our weekly newsletter

Follow us

Facebook Twitter Linkedin Weixin Weibo Youtube

Subscribe to Our Free eNewsletter

Subscribe

Check out our content with some of our syndication partners

factiva

Recent Articles

Weathering storms, Unisplendour lets its performance speak

Reborn Unisplendour trades in chips for digits

The new rendition of former chip highflyer Tsinghua Unigroup is charting a pragmatic course, shifting from M&A-driven expansion to digital infrastructure Key Takeaways: Unisplendour has filed for a Hong Kong…
000938.SHE